For many years medical scientists have been able of producing a variety of "inappropriate" seeking an ideal and reliable "cancer test". Many factors such as the "ectopic" hormones and oncohave been proposed; none has stood the test of fetal antigens (for reviews, see Laurence and dctailed:and critical evaluation. With the demonstra- Rees and Ratcliffe, 1974) there has tion)hat many, if not all, human tumours are cap-been a renewed interest in biochemical approaches to cancer diagnosis. The role of measuring such tumour index substances in plasma and/or urine and their use as biochemical and immunological markers to facilitate the detection of neoplastic disease has been submitted recently to detailed appraisal. None has been found to be specific for malignant disease, so that their value is minimal in detecting localized primary cancers or in their differential diagnosis. The experience gained from these studies, however, has served to focus attention on their possible role in monitoring the progress of diagnosed tumours and their response to therapy. The results of the treatment of many forms of cancer by surgery and/or radiotherapy appear to be entering a plateau and wider use of new modalities of therapy, especially chemotherapy, may well be indicated. However, although statistical analysis may show that only 50 %of patients with an apparently successful excision of a cancer will remain tumour-free at five years, the eventual fate of the individual patient cannot be foretold at the time of completion of the definitive treatment of the primary tumour.
Hence the doctor is faced with the dilemma of subjecting the cured patient to increasing chemotherapy or waiting until there is obvious clinical evidence of metastases, by which time it may be too late for the therapy to have any real benefit.
The objectives of cancer monitoring systems are: (1) to provide for the earlier detection of recurrences or metastases by giving a lead time over other methods of tumour detection; (2) to aid the assessment of the rate of progression of established metastases;
(3) to act as an indicator of the response to treatment; and (4) to act as prognostic indices.
Suitable biochemical markers fall into two groups. Firstly, there are the products of tumours, which may appear in the plasma or urine. These products may be derived from the tumour cells themselves or its stroma, and may be regarded as appropriate (to the tumour type) or "inappropriate". Either type of product may have known biological or metabolic activity (e.g., hormones, enzymes) or be without known functional properties (e.g. some of the oncofetal antigens). Secondly, there are tumourassociated changes which involve a variety of plasma or urinary parameters, including enzymes and proteins. These changes may be mediated by the products themselves of the various neoplasms and/or their particular primary or metastatic locations. Some marker substances of potential value are catalogued in Table 1 .
In this presentation rather than attempt to be totally comprehensive we propose to concern ourselves with the commoner tumours and to highlight some factors of established value in monitoring and other factors, which appear at present to have potential and which may have applicability in the future. CEA is a glycoprotein, molecular weight approximately 200 000, and is an example of an oncofetal "antigen" which is found in the alimentary tract, liver, and pancreas of fetuses between the second and sixth months of intrauterine life and initially in primary and metastatic colorectal carcinomas (Gold and Freedman, 1965) . With the development of sensitive radioimmunoassays, CEA (or CEA-like material) was also detected in normal adult tissues, different types of tumours and the plasma of such patients, and in many body fluids (see review by Neville and Laurence, 1974) , thereby refuting its initial gastrointestinal specificity (Thomson et al., 1969) .
Raised CEA levels occur in the plasma of patients with a wide variety of histogenetically different tumours and with numerous inflammatory and nonneoplastic states ( Table 2 ). The precise CEA levels, in numerical terms, will vary in accordance with the type of radioimmunoassay employed. Nonetheless, all the available methods seem to give largely comparable results (LoGerfo et al., 1971; Chu and Reynoso, 1972; Egan et al., 1972; Boenisch and Raam, 1975) . In tumours the plasma levels are predominantly related to the extent and site of tumour spread or tumour volume (Laurence et al., have been clinically overt (Table 3 ). In 26 of these patients the plasma levels became elevated and rose to higher levels between 3 and 18 months prior to the detection of recurrent or metastatic disease (Fig. 1) . In a further 17 subjects, apparently well at this time, rising CEA titres have also been detected, which may allow the conclusion that they too now have recurrent or metastatic disease, which, however, remains latent asjudged by other clinical and physical diagnostic methods (Table 3 ; Fig. 2 ). In them the lead time given by rising CEA levels may be in excess of 18 months. and of Barralet and Mach (1975).·· 1972; Mach et al., 1974; Barrelet and Mach, 1975; DiSaia et al., 1975) , which, together with the "false positive" results found in non-neoplastic situations, limit and even possibly negate its use for diagnosis and differential diagnosis. It has been suggested that sequential assays of CEA may be of greater diagnostic value in that rising tit res may be indicative of neoplasia and steady or declining values of active or resolving inflammatory disease. While this may be true, such studies in ulcerative colitis have failed to indicate the onset of premalignancy or frank carcinoma (Booth et al., 1974a) .
The most important present clinical role for plasma CEA is in surveillance to facilitate the earlier detection of recurrent or metastatic tumours known to be associated with the production and release of CEA. Most studies to date have concentrated on colorectal carcinomas (Booth et al., 1974b; Mach et ai., 1974; Mackay et al., 1974; Sorokin et al., 1974; Turner, 1975) . We have been carrying out a combined study of a large number of patients in Leeds and the South-west Thames Region after clinicalIy curative surgery. Their plasma CEA levels have been measured at each return reassessment outpatient visitand compared with other clinical and laboratory evidence of recurrence. 220 patients have now been reassessed continuously for at least two years, and raised plasma CEA levels (> 40 ngjrnl) have developed in 36 of 53 subjects in whom recurrences .Normal value of plasma varies numerically depending upon the assay system used.
• ·Series A, Mackay et al, (1974) ; Series B, Mach et al, (1974) ; Series C, Booth et al, (1974) . ···No evidence of recurrence. the levels fell again after operation in patient 2 (0----0) a steady rise occurred tbereafter, and similar trends are seen in patient 3 ( . .) although tbe preoperative level was normal. In patients 4 and 5 (0---0; /':, ----/':,) normal CEA titres were found at the first postoperative analysis, but rising levels bave since been recorded. 71_ /1081 fIIIWYI' ' ' ' . In drip zo 40 zoo and GGT seems to represent a significant addition to the patient surveillance armamentarium available to the clinician to detect recurrences or metastases.
Similar studies, but on a much smaller scale, have been conducted for other tumours with essentially similar results in female genital cancer Mackay, 1973, 1974) and bronchial carcinoma (Vincent and Chu, 1973) , where significant lead times have been provided by rising CEA titres in many, but not all, patients. However, experience of mammary (Chu and Nemoto, 1973; Bettelheim et al., 1975) and of urothelial carcinoma indicates that in only a minority of such patients will rising CEA titres be detected prior to the overt development of metastases (Figs. 4 and 5) . Such rises are too inconsistent in our hands to be clinically valuable in these disorders at present, and improved assays with reagents more appropriate to those tumours are required. Such a search, however, is important if earlier and more appropriate chemotherapeutic and/or radiotherapeutic measures are to be instituted. CEA or CEA-like materials were detected in the urine of patients with urothelial malignancies, and it seemed that their assay might have a value in monitoring local recurrences (Hall et al., 1972) . However, further sequential studies have shown that infection yields high levels, which vitiates the usefulness of the assay. Moreover, urinary cytology was as accurate a method of detecting local disease . Studies have shown that much of the urinary material, detected as CEA in the assay, is chemically different from coloncarcinoma-derived CEA and that a more appropriate assay system is needed before any clinical usefulness can be attained Nery et al., 1974) .
There are now several studies of the potential role of plasma CEA assays to aid in monitoring the efficacy of antitumour therapeutic regimens (Vincent and Chu, 1973; Chu and Nemoto, 1973; Neville and Laurence, 1974; Skarin et al., 1974; Steward et al., 1974; Mackay, 1973, 1974; Barrelet and Mach, 1975; Di Saia et al., 1975) . While a decline in the postoperative period of plasma CEA levels to the normal range may be associated with complete surgical removal of the tumour, such a fall can occur in the presence of small amounts of residual disease. On the other hand a continuing rise or only a partial decrease in the levels in the postoperative phase are generally equatable with progressive disease and early clinical recurrence.
Successful radiotherapy or chemotherapy with a decreased tumour load can be associated with declining plasma CEA values, though not all subjects exhibiting a good clinical response will show such a fall (Barrelet and Mach, 1975) . Moreover, such a decline in the CEA level does not reflect quantitatively changes in tumour volume in the manner which HCG assays mirror alterations in the number of cells of a gestational choriocarcinoma (Bagshawe, 1969) . A further problem in the interpretation of CEA values is related to the transient rises which may occur shortly after institution of such therapy (Bagshawe et al., 1973) . This appears to be due to the induced tumour necrosis and the resulting release of CEA or CEA-like materials (Khoo and Mackay, 1973) .
Notwithstanding these deficiencies the present consensus would appear to be that sequential plasma CEA assays give some indication of therapeutic efficacy. Rising or stationary but elevated titres would also seem to indicate the need for additional or changes of therapy. Some successful outcomes have been Doted in this respect (Skarin et al., 1974; Steward et al., 1974) . Progression of disease, however, may occur without any change in the CEA level, and clinical or radiographic demonstration of disease regression or progression may precede any significant alteration in the CEA levels (Chu and Nemoto, 1973) .
Increasing attention is now being paid to the possible use of adjuvant chemotherapeutic regimens prior to the overt clinical re-emergence of disease. Selection of suitable patients would be facilitated in disease where rises in a tumour index substance Mackay et al. (1974) and LoGerfo and Herter (1975) . Normal value varies depending upon assay system,', .. radioimmunoassay developed. Its value in monitoring and diagnosing various tumours has been assessed ( Fig. 6 ); no tumour situation has yet been outlined where rising CCEA-2 titres have preceded those of CEA. Its addition to the battery of tests, thus, does not seem warranted at present. The lXI-globulin, AFP, is a product of the fetal liver, gastrointestinal tract, and yolk sac which appears in the fetal circulation (Gitlin, 1971) . Its principal present clinical use is in obstetrics, where high concentrations are present in the amniotic fluid in association with fetuses having neural tube defects, certain forms of nephrosis, or a 45/XO chromosomal constitution (Allan et al., 1973; Brock et al., 1973; Leek et al., 1973; Seller et al., 1973; Seller et al., 1974) . In addition raised AFP titres in plasma or urine give a significant lead time and where their assay also yields a useful prognostic sment.
_
In carcinoma of the colon and rectum it is now well established that a significant lead time may be given by monitoring the plasma CEA levels (vide I"pra) . Some recent studies have claimed that the preoperative plasma CEA level may act as a prognostic index (LoGerfo and Herter, 1975; Zamcheck et 01., 1975) , as raised titres increase the chances of recurrence developing within 3 years after operation, by about a factor of two. All the available data have been re-examined and 300 patients have been followed up from the preoperative time: 131 have developed recurrences, of whom 85 had raised preoperative CEA levels; 169 remain alive and well and without known disease, of whom 59 had raised preoperative values. The data have been grouped according to Duke's staging, when it may be seen that a raised titre tends to carry a worse prognosis (Booth et al., 1974b; Mackay et 01., 1974) (Table 4 ), but many other factors must be operative as the relationship is far from clear-cut. Certainly these data point to the necessity of improving our true operative staging of the disease before plasma CEA levels can be interpreted as a meaningful indicator of prognosis.
In breast carcinoma, sequential plasma CEA assay yields a useful lead time in only a limited numbertoo few to be practically important at this time. From our own three-year follow-up study we have at present found no prognostic relationship between the preoperative CEA level and the eventual outcome. However, a recent study of postoperative CEAlevels has shown that they may have significant prognostic value. Whereas a recurrence rate of 20 % was found in those women with normal postoperative levels, a 65 %recurrence rate was noted in those with high levels (Wang et al., 1975) .
Consequently, it would seem that plasma CEA levels may assist in defining poor prognostic groups who might benefit from adjuvant chemotherapy. Moreover, by monitoring the levels of CEA thereafter, the detection of developing and progressive disease might be facilitated when appropriate therapy and its monitoring could be instituted with hopefully improved results.
A further glycoprotein referred to variously as NCA (von Kleist et 01., 1972) , NGP (Mach and Pusztaszeri, 1972) , CEX , CCEA-2 and BCGP (Kuo et 01.,1973) has been found in normal and neoplastic human colonic tissue but has also been shown to be a product of circulating mononuclear cells (Martin, '974) . This material has been purified (Turberville et 01., 1973) , monospecific antisera raised. and a lQCXX] occur in the plasma of pregnant women with Rh-immunization or diabetes and pathological levels are also seen in conjunction with fetal distress (Seppala and Ruoslahti, 1973) . After birth AFP levels decline to reach a base line at the age of 2 years, maintaining this low level (2.6 ± 1.6 ng{ml) throughout adulthood. A small rise may subsequently occur after the age of 60 years (Massayeff et al., 1974) . Consequently, as with CEA, AFP production, though significantly lowered postnatally, is not completely suppressed.
Early oncological studies appeared to indicate that AFP exhibited a tumour specificity for primary hepatocellular carcinoma; with the development of sensitive radioimrnunoassays, however, such a specificity has been lost. Although often not reaching the levels found in association with hepatomas, AFP (or AFP-like materials) occur in raised amounts in the plasma in association with numerous different types of malignant tumours and in inflammatory and regenerative conditions (Table 5) .
Almost all hepatomas produce AFP, but in 
0···
• From the data of Ruoslahti et al. (1972) , Purves et al. (1973) , Silver et al, (1974a, b) . et al., 1975) .
widely differing amounts (Purves et al., 1970) . Plasma levels seem to be unrelated to tumour size; nodular and poorly differentiated tumours tend to be associated with the highest levels (Glazer et al., 1974) . Extensive studies in gold miners, who have a high frequency of hepatomas, have failed to reveal a preclinical phase where plasma AFP is raised in the absence of clinically detectable tumours (Purves et al., 1973) . This, together with its lack of specificity, tends to limit its role in early and differential diagnosis (Table 5 ). From clinical and experimental studies it would appear that raised levels in non-neoplastic liver disease reflect the response of the liver to the injury rather than the severity of damage and occur in association with the regenerative phase of these disorders. With complete recovery the levels return to normal Silver et al., 1974) . Elevated levels of serum AFP occur in many patients with gonadal malignant teratomas (Tables 6   and 7 ), the precise number depending largely onthe extent of disease. In our own series (Grigor et al., 1975; we have found elevated values in approximately 65 % of patients with malignant teratomas, including those with seminomatous and/or trophoblastic elements. In addition yolk sac tumours give raised levels ( Table 6 ). The degree of differentiation of the teratoma is not as important in'determining the level as the extent of disease, the values being highest in stages III and IV (Grigor et al., 1975) . Seminomas do not appear to produce AFP (Table 6 ).
Recent surveys of many other tumours have shown that a variety of entodermally derived lesions may be associated with raised serum titres (Table 5) . Such titres, however, are not frequently in excess of 150 ngjml. Most positive examples occurred with gastic and pancreatic carcinomas, many of which were associated with hepatic metastases (McIntire et al., 1975) . In our experience of over 50 patients with colorectal and bronchial carcinomas with widespread metastases less than 4 % had elevated values (Grigor et al., 1975) . Moreover a wide variety of other tumours with dissemination at the time of testing, including mammary, ovarian, and urothelial carcinomas, lymphomata, and sarcomata, have failed to disclose a single positive case. Similar findings have been reported by McIntire et al., (1975) .
Consequently, it appears at present that, in the field of oncology, AFP assays may have a useful role in only hepatic, gonadal, gastric, and pancreatic neoplasia.
The role of AFP assays in monitoring disease, its recurrence, progression and response to therapy, has been studied in too few cases to date to assess its The assay of more than one parameter may be of assistance in monitoring the therapy of tumours. For example, some gastric carcinomas produce CEA, others AFP, and a few both antigens (Ravry et al., 1974) . This same concept of rnultiparametric assays has relevance to teratomas. 47 %of our AFP positive cases also had raised RCG levels in the plasma, while 16 % of the AFP negative cases had raised levels.
Most of these tumours did not show any evidence of trophoblastic differentiation. Thus, HCG represents a useful second monitoring system, irrespective of the histology, and should be carried out in all cases. This is re-emphasized by the findings of Braunstein et al., (1973b) , who noted a discordant fall in the AFP and RCG levels in a teratoma in response to therapy and also differential rises with disease progression. Such changes may be due to AFP In teratomas successful surgery, radiotherapy, and/or chemotherapy results in a decline in the serum AFP to normal (Table 6 ; Figs. 7 and 8). Sequential studies of AFP thereafter indicate that rising titres can develop before or coincident with the reappearance of recurrent or metastatic disease.
Number of Patients
It is too early, however, to state the number of cases which will show such a trend or to assess the useful lead time. In gastrointestinal AFP-producing lesions a lead time has also been noted (Mcintire et al., 1975) . Caution is needed, nonetheless, as recurrences can develop without rising APP titres (Esterhay et al., 1973) . AFP may serve as a therapeutic monitoring substance for patients with teratoma ( Figs. 7 and 8) . McIntire et al., (1975) and Purves et al., (1970) have also reported similar findings in gastrointestinal and hepatic neoplasia. Nonetheless, while rising titres may indicate drug ineffectiveness, clinically observable progressive disease may take place in the absence of changing AFP levels. While in experimental hepatic neoplasia it has been proposed that the AFP levels reflect the number of proliferating tumour cells (Wepsic et al., 1974) , this relationship does not appear to apply to non-hepatic AFP-producing tumours. Indeed, the cell type(s) which produce AFP in teratomas or ether tumours still remain to be identified by cytological techniques. ·Dala of Grigor et al. (197S) ; normal. < 2Sng/ml. and HCG synthesis by different tumour cell types and their variable sensitivity to chemotherapy (Figs. 7 and 8) .
Finally, the molecular size of AFP will allow its passage through the renal glomerular basement membrane. Its detection in urine may afford a further method of monitoring neoplastic disease (Rosenmann et al., 1974) .
(c) Other oncofetal and tumour-associated antigens
Many other oncofetal antigens have been detected in relation to various forms of human neoplasia Coggin and Anderson, 1974; Hakkinen, 1974; . Some look promising and potentially useful, but results of studies in relation to monitoring various tumours are still awaited.
In addition a whole series of tumour-associated or tumour-specific antigens have been defined in immunological terms. Some, such as the cancer basic protein and the MEM test, seem to have no clinical role in monitoring disease and solely may be of value in its initial diagnosis Caspary, 1970, 1971; Pritchard et al., 1973) . Much further clinical and chemical work is needed to clarify their various roles in our armamentarium to monitor cancer.
Hormones
Many tumours of the endocrine glands secrete their appropriate hormones, which properties have been extensively used in their diagnosis and treatment. In a similar way the production of RCG by trophoblastic tumours has been well documented and found to be of inestimable value in the control of this disorder (Bagshawe, 1969) . These lesions are rather rare, and when the ectopic production of hormones by "non-endocrine" tumours was demonstrated it appeared as though this approach would be of broader oncological value. This phenomenon has been documented now in association with most tumour types, though certain neoplasms tend to be more commonly associated with the formation and release of particular hormones. Various aspects of these syndromes together with theoretical causative molecular mechanisms have been discussed and extensively reviewed recently (Rees and Ratcliffe, 1974; Ellison and Neville, 1973) .
The property of ectopic hormone production is most readily apparent in bronchial carcinoma; its incidence, however, remains small (Table 7) . While isolated reports of their value in making the initial diagnosis have been documented (Rosen et al., 1968) , their principal value would appear to lie in the field Bronchial cancer ·From data of Rees and Ratcliffe (1974) .
of detecting recurrent tumour and monitoring of therapy. The problem often, however, is their relative rarity and that significantly raised levels tend to be detected late in the disease.
(a) Calcitonin An exciting example of ectopic hormone production, which appears to be far from rare, has been described recently and is the release of immunoreactive calcitonin by a variety of tumours, in particular mammary and bronchial carcinomas (Coombes et al., 1974) . In-vitro tissue culture studies have shown its production and release by mammary (9/15) and lung (3/9) cancer cells and it is possible to extract it from these tumours but not corresponding normal control tissues or benign conditions so far examined (Ellison et al., 1975) .
Plasma levels of calcitonin are largely dependent on stage and tumour load (Table 8 ) and help in the discrimination of local from disseminated disease. Of importance is the finding of raised levels in those with apparently localized disease or "no" evidence of disease after operation (Table 8) . One of this group has now developed overt metastases. Hence the use of calcitonin, at least in breast cancer, to monitor disease activity and the effect of therapy and to detect recurrences prior to their overt clinical presentation looks promising (Fig. 9) .
In medullary carcinomas of the thyroid it is possible to provoke increased secretion of calcitonin by the administration of known stimuli such as to human medullary carcinoma-derived calcitonin. However, in one lung carcinoma larger molecular weight material with biological and immunological activity has been observed. It may be possible in the future to prepare antisera which will discriminate between these various "calcitonins" and which may have clinical relevance.
(b) Prostaglandins
While the ectopic production of parathyroid hormone and certain precursor molecules and fragments are known to occur in neoplasia (Benson et al., 1974 ) the frequency of this mechanism would appear to be too small to explain the occurrence of hypercalcaemia in cancer-bearing subjects (powel1 et al., 1973) , especially those with breast cancer (Powles et al., 1973a, b) . The latter group of authors indirectly implicated the prostaglandin group of compounds as possible causative agents, since when they have continued their studies and have now shown the in-vitro release by over half of the examined mammary carcinomas of prostaglandins . This gives a close link with the hypercalcaemia induced in mice by a prostaglandin E 2-producing transplantable fibrosarcoma (Tashjian et al., 1974) . However, in women, other osteolytic factors, possibly peptides, are also released in-vitro by human breast tumours. This factor may be related to the hypercalcaemic agent formed by an experimental rat Leydig cell tumour (ponthier and Rice, 1974) .
In the mouse increased prostaglandin levels are detectable in the animals bearing the tumour. While the celI sources of these various osteolytic principles remain to be identified, they as a group hold significant promise for the future monitoring of breast carcinomas and make an interesting study of their role in facilitating bone metastases, so frequent in this disease. gastrin or whisky, whose action is presumably mediated by the gastrointestinal hormones. If suchagents can be found to be effective in calcitoninproducing mammary carcinomas, then such a provocative test may have great practical importance in detecting even earlier latent metastatic disease. Extensive tissue culture studies are now in progress aimed at finding suitable stimulating agents (Ellison et al., 1975) .
The final area of interest rests in the chemical nature of the calcitonin produced by non-endocrine tumours. Preliminary data suggest that in breast and some, but not all, bronchial carcinomas the "ectopic" calcitonin is of a similar molecular size • 1975.) has been the recent recognition that such hormoneproducing tumours may also form and release related materials or subcomponents of the hormones (Rees and Ratcliffe, 1974; Rosen et al., 1975) . In the ectopic ACfH syndrome, for example, three related materials-CLIP, N-terminal fragments of ACfH, and fJ-MSH-not present or present only in trace amounts in the normal pituitary may also be formed by the tumours. Their role as tumour index substances remains to be ascertained. A variety of placental products are known to be produced by non-trophoblastic tumours, their formation being analogous to the production of oncofetal antigens. Approximately 5 % and 12 % of tumours, most commonly ovarian, gastric, pancreatic, hepatic, and lung carcinomas (Braunstein et al., 1973a, b, c; Rosen et al., 1975) , produce HPL and HeG respectively. In addition such tumours may also produce the free ex or fJ subunit of HCG, though these subunits can be released in isolation without concomitant HCG production (Franchimont et al., 1972; Weintraub and Rosen, 1973; Rosen and Weintraub, 1974; Rosen et al., 1975) .
A series of clonal cell lines have been established from an HCG-producing bronchial carcinoma when the isolated and imbalanced production of HCG and its at and fJ subunits was demonstrated (Tashjian et al., 1973) . This observation of multiple markers not formed in parallel has important therapeutic significance if the full spectrum of tumour cells is to be followed.
A series of patients with disseminated tumours and producing HCG or its subunits have been followed sequentially and the effects of chemotherapeutic agents assessed (Rosen et al., 1975; Rosen and Weintraub, 1974) . In most instances concordance of HCG levels and the clinical course was encountered.
Milk proteins
Two milk proteins, casein and lactoferin, have been examined for their role in the diagnosis and monitoring of breast cancer.
Casein is a normal milk constituent whose exocrine production by the mammary gland is under hormonal control (Turkington, 1971) . It consists of a series of related phosphoproteins for which a radioimmunoassay capable of detecting it in plasma has recently been developed (Hendrick and Franchimont, 1974) . Only a minority of healthy male and female subjects and pregnant women have detectable circulating levels, though in lactation high values are the rule. A few patients with mammary carcinoma exhibit raised preoperative values; how-ever, many after surgery and/or radiotherapy have raised titres whose significance is unknown, as no statement of the stage of disease was included. Nonetheless, in recurrent disease or with metastases elevated levels can be found, which may mean that serial assay of serum casein may be of value in monitoring and treating the disease. The marked overlap of the levels with other patients without disease is unfortunately a limiting factor which will need to be overcome by improved assay methods.
It is also claimed and is of potential interest that casein may be an "ectopic" product of some bronchial and gastrointestinal carcinomas (Hendrick and Franchimont, 1974) .
Lactoferin is another milk constituent whose role in monitoring mammary disease has been evaluated. Its presence in circulating monocytes tends to preclude its having a useful clinical role at present (Rumke et al., 1971) .
Methylated nucleosides and pseudoridine
Methylated nucleosides and pseudouridine are found predominantly in transfer, and to a less extent, microsomal RNA (Dunn, 1959) . Higher levels of these compounds have been reported in both animal and human tumours than in the appropriate normal control tissues, and this may be reflected by raised levels in the urine and plasma of tumour-bearing subjects (Adams et al., 1960; Weissman et al., 1957; Dlugajezyk and Eiler, 1966; Levine et al., 1975; Waalkes et al., 1973; Tormey et al., 1975) .
These increased levels in neoplasms may reflect tRNA degradation. Nucleic acid bases are methylated only after formation of the RNA macromolecule, so that their presence in the blood and urine may be a measure of tRNA degradation. The excretion of pseudouridine, which is not reutilized, is thought to be a measure of tRNA turnover, while the elevated methylated nucleic acid bases may reflect the increased tRNA methylase activity known to occur in tumours, though it may too be a reflection of tRNA turnover. Nonetheless, some of these changes could also be caused by the effect of the tumour or tumour products on tRNA turnover by other cells of the host other than the neoplastic ones.
In recent years increasingly sensitive and specific methods with clinical applicability have become available for their measurement in urine and plasma, including gas-liquid chromatography-mass spectrometry and radioimmunoassay (Waalkes et al., 1973; Chang et al., 1974; Levine et al., 1975) . Particular attention has been paid to pseudouridine, and the methylated bases-e-N", N2-dimethylguanosine and I-methylinosine.
Increased urinary excretion of one, two, or all three of these materials has been demonstrated in a wide variety of tumours, including carcinomas of the breast, bronchus, ovary, testes, melanomas, lymphomas, and Hodgkin's disease and chronic and acute leukaemias (Chang et al., 1974; Waalkes et al., 1973; Fink and Adams, 1968; Weissman et al., 1963. In addition elevated plasma levels of pseudouridine and N2,N2-dimethyl-guanosine occur in the sera of patients with acute leukaemia and manywith breast cancer (Levine et aI., 1975) . Unfortunately the stage of spread of these lesions was not stated, but other data suggest that the urinary levels tend to rise higher with more advanced disease (Tormey et al., 1975) .
Thus, it may be that although elevated levels may also be found in inflammatory diseases such as arthritis and psoriasis (Weissman et al., 1957; Dlugajczyk and Eiler, 1966) , these materials measured in either urine or serum or both will represent further products which may be of value in the followup appraisal of cancer patients. In lymphoma and leukaemia their levels are known to return to normal with successful therapy (Hogan et al., 1970) .
Polyamines
The short-chain aliphatic polyamines, spermine and spermidine, together with their precursor diamine, putrescine, are present in all nucleated cells. They have an important regulatory role in cellular growth in modifying the biosynthesis and functions of nucleic acids (Stevens, 1970) , to which they have a strong affinity owing to their polycationic nature (Tabor and Tabor, 1972) . Increased
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tissue polyamine levels correlate with rises in protein synthesis and are found in rapidly growing and metabolizing tissues (Snyder and Russel, 1970) . This and the fact that polyamines are not extensively catabolized (Russel, 1973) is consistent with the occurrence of raised polyamine levels in experimental neoplasms, regenerating liver, in the urine and sera of cancer-bearing subjects and in the cerebrospinal fluid of patients with primary and secondary brain tumours (Marton et al., 1973 (Marton et al., , 1974 .
Increased urinary and serum polyamine levels occur in association with a wide variety of malignancies, including carcinomas of the gastrointestinal tract, ovary, breast, and prostate, sarcomas, lymphomas, and leukaemias (Russel et al., 1971; Denton et al., 1973; Fair, 1975; Lipton et al., 1975; Marton et aI., 1973) . Most of the subjects, however, had advanced disease.
The most recent work (Fair, 1975; Marton et al., 1973 Marton et al., , 1974 has found that spermidine is the polyamine most often raised in urine, blood, and the C.S.F. in neoplasia, and there is a possibility, at least for prostatic carcinoma, that its levels bear some relationship to tumour stage and degree of differentiation (Table 9 ).
Assay of polyamine levels has been proposed as a tumour diagnostic aid. However, inflammatory and regenerative conditions can also lead to increased levels thereby vitiating any useful role (Lipton et al., 1975) . Nonetheless, they may be of some value to monitor the efficacy of surgical and chemotherapeutic regimes (Russel et al., 1971; Denton et al., 1973) , but further detailed clinicopathological studies with improved methods (Marton et al., 1973) are needed before their place in cancer monitoring can be truly assessed. *From data of Fair (1975) .
TUMOUR-DERIVED PRODUCTS AND TUMOUR-AssOCIATED CHANGES

Enzymes
A great variety of enzymes and isoenzymes have been shown to alter in the tumours themselves and in the body fluids of cancer-bearing subjects. Often a reversion towards fetal isoenzyme patterns is noted (Schwartz, 1973; Shapira, 1973) . Alone or in combination these enzyme changes, whether of tumour origin or induced by the presence of the lesion, have with few exceptions been considered as rarely pathognomonic for cancer owing to their relative nonspecificity. Yet once the diagnosis for cancer has been established, serum enzyme measurements can provide a valuable contribution to a battery of tests designed to monitor the patient's progress (Steele et al., 1974; Cooper et al., 1975a) . In using serum enzymes in this way, caution must be taken in the interpretation of the significance of changes in their levels of activity, since many of the enzymes that are chosen for their sensitivity as monitors of the presence of tumour may well be extremely sensitive to other forms of acute and chronic illness, some of which may, by chance, develop while the patient is under surveillance. Confidence that the change in activity is an indicator of cancer is usually greater when more than one of the parameters in a battery of tests is disturbed. The choice of the enzyme or battery of enzymes will depend on the nature of the primary tumour and the pattern of distribution of its metastases. It must be equally borne in mind that the load of metastatic cancer generally increases as a cascade phenomenon following the establishment of a metastasis in a key organ, such as the liver or the lung (Bross et al., 1975) . This may help to explain the likely rates of change, particularly in those tests which tend to reflect tumour mass. We propose to illustrate the use of enzymes in cancer monitoring by reference to certain key enzymes or description of their contribution to composite tests that are used for the surveillance of an organe.g., the liver-that is a common site of metastatic cancer. In addition some interesting recent developments will be high-lighted, though their value still remains to be ascertained in full.
(a) Acid phosphatase
Seventy-five to 90 % of patients with prostatic carcinoma which has metastasized to the skeleton have elevated serum acid phosphatase levels (Bodansky, 1975) . The extent of the increase varies considerably but tends not to be particularly high; Woodard (1952) reported an average value of 4.0 KA units in 107 patients with bone involvement. As a monitor of the disease serum acid phosphatase is a useful but not infallible indicator of spread to bone, or its extent. In many patients with bone metastases the level of serum acid phosphatase may fall in response to treatment with oestrogens or orchidectomy. Unfortunately in long-term studies it can be shown that extensive metastases can develop when a patient is on treatment that are not associated with a rise of acid phosphatase activity. Several methods have been proposed to increase the specificity of this enzyme measurement, such as the use of selected substrates which are specific for the prostatic acid phosphatases-s-e.g., ex glycerophosphate or ,B-naphthyl phosphate (Reynoso, 1973) . Fishman and Lerner (1953) proposed that the inhibition of serum acid phosphatase by t-tartrate was specific for prostatic acid phosphatase, but this method appears to offer little advantage over using a more specific substrate.
(b) Alkaline phosphatase and its isoenzymes
Elevation of alkaline phosphatase occurs in two main groups of cancers, those affecting the liver and those involving bone. Primary hepatomas, unlike metastatic tumours of the liver, tend to have normal serum alkaline phosphatase activities. Osteogenic sarcoma, especially of the osteoclastic type, often releases large amounts of alkaline phosphatase of bone origin into the circulation, but chondrosarcoma, Ewing's sarcoma, and giant cell tumour may have normal alkaline phosphatase activities (Bodansky, 1975) . Bone metastases from prostatic cancer and breast cancer may be associated with a rise of serum alkaline phosphatase; greatly elevated levels are more commonly seen in prostatic cancer.
A great deal of work has been effected with the placental isoenzymes of alkaline phosphatase referred to as the Regan isoenzyme (Fishman et al., 1968) as potential aids to monitor therapy and disease progress. Recent electrophoretic studies have shown that it consists of a series of different phenotypes, all of which may occur in the sera of cancer patients, though apparently only one type in each patient (Inglis et al., 1973) . In addition a further closely related isoenzyme has been noted to be a product of hepatocarcinoma (Higashino et al., 1974) .
These isoenzymes have been reported to occur in the sera of approximately 12 % of patients with a wide variety of different tumours (Nathanson and Fishman, 1971; Belliveau et al., 1974) . More recent studies, however, with different methodologies have failed to confirm such a significant number of elevated isoenzyme levels (Jacoby and Bagshawe, 1972; Usategui-Gomez et al., 1973; Cadeau et al., 1974) , so that the general and wide applicability once considered appropriate is now less certain. In addition early studies considered that the elevated levels were directly related to the tumour mass (Stolbach et al., 1969) but this is now open to doubt. Nathanson and Fishman (1971) noted that it could serve as a useful agent to judge the efficacy of surgery and/or chemotherapy in some cases of carcinomas of the ovary, breast, colon, and pancreas while also reflecting, by rising titres in other patients, disease progression and therapeutic refractoriness. Other recent work must now also cast doubt on this role, as in some patients with haemopoietic tumours Belliveau and his associates (1974) failed to find any relationship between the Regan isoenzyme levels and disease activity.
Consequently it would appear that in view of the fact that only a minority of subjects will have a raised Regan isoenzyme level and that its role in the follow-up phase and disease monitoring is not yet determined, further studies are needed to clarify these points before it can be recommended for routine oncological practice.
(c) Prolyl hydroxylase
The enzyme prolyl hydroxylase, which plays an important and essential part in collagen biosynthesis, is known to be present in increased amounts in hepatocellular carcinomas and to be elevated in the serum of approximately 50-70 % of those patients (Braunstein et al., 1973a; Glazer et al., 1974) . This observation has been recently confirmed and extended to show that the combined use of serum prolyl hydroxylase and AFP assays will result in the identification of all patients with hepatocellular carcinoma . Experimental studies have shown that prolyl hydroxylase levels rise early in the premalignant phase making its assay of potential value in detecting such tumours in high risk populations .
A further exciting development has been the identification by immunocytochemical methods of prolyl hydroxylase in human breast carcinoma cells. The results of using serum assays of this enzyme to monitor breast carcinoma patients is now awaited with eager anticipation.
(d) 5'-Nucleotide phosphodiesterase
A similar type of analysis has been suggested recently by Tsou et al., (1974) in their studies of the appearance of an isoenzyme of 5'-nucleotide phosphodiesterase. Its occurrence in the serum is strongly indicative of primary or metastatic cancer
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in the liver and seemed to be more sensitive than ee-fetoprotein assays for the detection of hepatoma (38/43 isoenzyme positive, 6/43 ee-fetopretein positive by immunodiffusion). This observation will need to be checked against a series of sera from patients as they pass from microscopial hepatic metastases to overt clinical disease to find out its potential contribution to cancer monitoring. It is possible that in some patients it could be very sensitive yet in others it would detect only advanced tumours or be totally insensitive. This illustrates the influence of chance factors of isoenzyme selection that may provide the basis of a very sensitive test in certain individuals, but a negative test would have no significance.
(e) Sialyltransferase
It is now well established that many cell surface changes are demonstrable in transformed and cancer cells.
One of the changes involves the surface glycoprotein which may have higher levels of sialic acid. Recently Bossmann and Hall (1974) demonstrated raised sialyItransferase levels in human mammary and colonic carcinomas compared to their related normal counterparts. Now Kessel and Allen (1975) have measured plasma sialyltransferaso levels and found them raised in a large number of patients with a variety of neoplasms including breast, lung, colon, and leukaemia. In such patients, it is presumed that the increased sialyltransferase levels are of tumour origin; usuaIly plasma sialyltransferase is derived from the liver (Kim et al., 1972) . Hence raised levels might be expected in some active hepatic diseases. They have also been noted in rheumatoid arthritis, and so increases are in no way cancer-specific. Nonetheless, some of the patients studied by Kessel and Allen (1975) had only small amounts of tumour with raised levels above those noted in inflammatory disease. They also claim that there may be a relationship between the plasma level and the tumour mass. Of interest is the finding of declining levels after operative removal of a tumour.
In some experimental animal tumours, plasma levels of sialyltransferase may be related to their metastasizing ability, being highest in those with the greatest inherent metastatic capability (Bossmann et al., 1973) .
These initial pilot studies taken together with the experimental evidence are sufficiently encouraging for others to examine its role in cancer monitoring in some detail.
(f) Lysozyme
Plasma concentrations show characteristic disturbances in acute leukaemias, being low in the lymphatic leukaemias and elevated in myeloid leukaemias and very high in myelomonocytic leukaemias. Serial measurements show a return towards normality as the patient responds to therapy and can act as a monitoring system to be used in conjunction with the usual haematological examinations (Hansen, 1974) . Its real potential is for monitoring of the chronic myeloid leukaemias, particularly for giving an earlier warning of the onset of acute myeloblastic transformation. Adenosine deaminase seems to be coded by a single gene, the different isoenzymes corresponding to more or less aggregated forms (Hirschhorn et al., 1973) . The modifications in leukaemia (Bloom, 1972) are probably post-synthetic and might well be used for monitoring. So far no data from horizontal studies have been published.
Metastatic cancer of the liver
The detection of the involvement of the liver by metastatic cancer can be achieved many months before enlargement of the liver and sometimes one to two years before elevation of the serum bilirubin when the liver is involved with relatively slow growing metastases, particularly arising from the colon and rectum (Cooper et al., 1975a) . Our experience from the study of the evolution of hepatic metastases from colorectal cancer suggests that the pattern of biochemical change can be conveniently divided into a number of stages Steele et al., 1974; Cooper et al., 1975a) .
The first stage may be completely silent, from the point of view of serum alterations of CEA, enzymes, and acute phase reactant proteins. This is the situation that can occur when very small metastases have been demonstrated at laparotomy and have subsequently been proved to be undetectable for several months by the methods that we are using in our monitoring systems. As far as enzyme changes are concerned, the first indication of hepatic involvement is a slow rise in the level of gamma glut amyl transpeptidase activity above the upper limit of normal (30 IU/1 = 95th percentile) to a value of up to about 100 IU/l. During this period, which may take many months, there is usually a coincident or an antecedent rise in blood CEA level (vide supra).
The next phase is the continuing rise of GGT, usually at a faster rate. accompanied by the recruitment of other markers of liver involvement such as the rise of 5-nucleotidase, alkaline phosphatase, leucine aminopeptidase, and the serum transaminases. In the untreated patients the levels ofGGT tend to rise almost exponentially and can reach levels of 500 or 600 IUjl but without the patient necessarily having many symptoms. The ineffectiveness of successive measurements of alkaline phosphatase as an earlier marker of hepatic metastases compared to that of CEA has also been noted by Holyoke et al. (1975) . From the detailed studies that we have made in colorectal cancer it is our impression that the most reports, particularly those dealing with comparisons of various batteries of tests to discriminate metastatic cancer of the liver from other forms of liver disease, have in the main been concerned with the stage when metastases are well established and produce major patterns of biochemical disturbance. Remarkably little attention has been paid to the development of tests for minimum tumour load in the liver, and at present this is proving to be a somewhat refractory problem. In a similar fashion the tests available to us today, including the use of plasma CEA, are relatively insensitive to small amounts of tumour left behind after resection of the primary or which have formed metastatic seedlings from the peritoneal surfaces.
TUMOUR-AsSOCIATED CHANGES
Serum proteins
Quite apart from AFP, CEA, and other welldefined tumour products, there has been a longstanding interest in the wide spectrum of changes in the concentration of serum proteins in general which can be detected in patients with cancer and their role in its diagnosis and monitoring. Particular attention has been directed towards the so-called acute-phase proteins, including protein-bound carbohydrate. The consensus of current opinion is that such changes play little or no part in facilitating the earlier detection of localized tumours or in their differential diagnosis, because changes of a similar order of magnitude may be found with inflammatory and regenerative disorders and with benign tumours (Alper, 1974; Evans et al., 1974; Koj, 1974; Randle et al., 1974; Rosato et al., 1971) .
It is not known how changes in acute-phase protein patterns are effected. These proteins constitute OCl,CX2, and fJ globulins; their plasma levels vary in response to injury, surgery, infarction, and infection, the collagenoses and in neoplasms (Alper, 1974) . It has been suggested that tumour necrosis may be responsible in part for effecting the plasma changes. However, this does not appear to be the case in lymphoreticular neoplasia (Cooper. 1975) , and tumour products of the tumours themselves affecting hepatic function could also play a part. The acute-phase proteins in disease may show a rise (positive reactants) or a diminution (negative reactants) in their levels. Those showing a positive response include haptoglobin, ocl-antitrypsin, OClantichymotrypsin, ocl-acid glycoprotein, fibrinogen, seromucoid caeruloplasmins, the C2, C3, and C4 components of complement and C reactive proteins, whiletransferrin is a negative reactant. These changes revert to normal with subsidence of the inflammation or injury. These observations thus lend support to the fact that the measurement of acute phase proteins may have a monitoring role in cancer.
Elevations are generally more pronounced in the presence of widespread metastases, but not all patients produce this reaction (Ablin, 1972; Suga and Tamura, 1972) . In a recent study of colorectal cancer, the ocl-globulins were raised in 44% of patients with metastases, but in only 9 % with primary and apparently localized tumours (Cooper et al., 1975b) . On the other hand the oc2-globulins were raised in 88 % with primary tumours and in 75 % with confirmed hepatic metastases. Moreover, 59 % of patients with normal plasma CEA and GGT levels after "successful" surgery and 58 %ofclinically well subjects but with raised CEA and/or GGT plasma levels, and presumably having occult recurrent tumours, had raised oc 2-globulin serum levels which were not due to oc 2-macroglobulin. Haptoglobin was also elevated in primary tumours and metastatic cancer, although in the tumour-free group with normal CEA and GGT, while many of the values were in the upper part of the distribution of normal values, a few were outside the range. Individuals observed repeatedly for a year or more and remaining tumour-free tended to have relatively stable values, suggesting that departure from their . own mean may be more important than the crossing of an arbitrary upper limit of normal as defined by the mean ± 2 S.E. of normal subjects. Haptoglobin levels have been found most valuable for monitoring ovarian carcinoma, particularly its response to chemotherapy (Mueller et al., 1971) .
This study has indicated an important group of postoperative patients with all other parameters in the monitoring system normal except for an elevated 112; it will be interesting to see if this is predictive of the eventual development of detectable metastases. Buffe et al., (1970) and Rimbault (1973) have reported a fetal ferritin-like oc2-globulin, called oc2H whichwas present in the sera of 80% of 452 children with cancer. When used as a monitor it was more sensitive than AFP for the detection of recurrent hepatoma in children being treated with chemotherapy. It was also able to give an early warning of recurrence of head and neck cancer in adults. Recently they have found oc2H globulin to be a potentially very valuable indicator in colorectal Biochemical monitoring of cancer 299 cancer (Buffe and Rimbault, personal communication) .
A fall in the oc2-globulins has been reported in prostatic cancer and gastric cancer (Ablin, 1972; Suga and Haije, 1972) as the result of response to therapy. In gastrointestinal cancer, the changes in the acute phase proteins are independent of the CEA levels (Suga and Haije, 1972) , an observation recently confirmed in a large series of colorectal cancer patients by ourselves and Booth et al., (l974a) .
While these preliminary results suggest that the inclusion of a spectrum of acute phase proteins may help to typify an aspect of the host-tumour relationship, it is still too early to say whether it will add a useful factor when assessing the patient's progress or prognosis. It may be that, in some patients, either as the result of the products made by a tumour or individual sensitivity to the signal, hyperproduction of acute-phase proteins may be sustained in the presence of small amounts of tumour that otherwise might have been undetected.
The seromucoid is a further member of the group of acute-phase proteins of which specific studies have been made, when elevations in its level in the serum were found in various malignant tumours, particularly once spread has taken place (Harshman et al., 1974; Randle et al., 1974) . While their levels revert to normal with successful therapy and pathological levels may be attained in association with recurrences, it is not yet known whether such changes may be used to indicate and monitor the extent of disease.
Other workers have concentrated their studies on the role of the serum glycoprotein fraction which occurs mainly as oc2-g1obulins (Barlow and Dillard, 1972; Evans et al., 1974; Macbeth and Bekesi, 1962; Rosato et al., 1971) . These too, have proved of little or no value in diagnosis, although some studies have indicated their usefulness in the assessment of disease extent (Shetlar et al., 1949; Almquist and Lausing, 1957; Macbeth and Bekesi, 1962) ; rises in the levels of protein-bound hexose appeared to correlate with the presence of metastatic disease. Other workers have noted rises in the amount of protein-bound fucose when expressed as a ratio of the total serum protein or of the protein-bound hexose in association with localized breast tumours, while the other protein-bound sugars showed rises only with metastases (Macbeth and Bekesi, 1962; Evans et al., 1974) . Of potential importance has been the finding during the follow-up phase that elevated protein-bound fucose levels may develop alone for periods of between 2 and 4 months before clinically overt recurrent disease can be detected (Evans et al., 1974) . Unfortunately other studies have failed to confirm this and tend to suggest that changes in Changes in the immunoglobulins are of great assistance in monitoring myelomas and related disorders due to the presence of M-components (Warner et al., 1974) . However, the detailed study of Talennan and Haije (1973) has shown that, fucose levels are also more indicative of disseminated disease (Barlow and Dillard, 1972; Rosato et al., 1971) . Successful therapy in those patients with raised levels is associated with a return of the levels to normal.
Consequently, if more specific fractions of the protein bound fucose (and/or hexose) can be identified and improved assays developed, it is possible that the sequential assay of such serum components may yield a further useful method of monitoring tumour extent and spread.
A number of other plasma proteins have been reported as being of value in cancer diagnosis and monitoring. These include {l2-microglobulin (Evrin and Wibell, 1973; Poulik et al., 1974; Kithier et al., 1974) , the serum T globulin or serum agglutinating factor, which is probably an cx2-macroglobulin (Tal and Halperin, 1970) and transcobalamine I (Carmel, 1975) . Like other tumour-associated changes they are not specific to neoplasia, and their role in assessing disease extent or to monitor therapeutic efficacy remains to be reported. One of the more interesting of these is the so-called pregnancyassociated macroglobulin (PAM).
The pregnancy-associated macroglobulin (PAM) is a high molecular weight (about 506 000) glycoprotein and known to occur in serum of pregnant women (Stimson, 1972) . Its chemical relationship to other serum macroglobulins such as T-globulin remains to be defined (Stimson, 1972) . This protein rises in titre during pregnancy and falls within six weeks of delivery to normal levels of less than 50 /Lg/ml. It appears to be released by peripheral blood leucocytes and macrophages and an immunosuppressive role has been suggested for one of its functions (Stimson and Blackstock, 1975) .
Using an enzyme-linked immunoassay, Stimson and Sinclair (1974) determined its level in a series of patients with a variety of tumours and elevated levels noted in association with mammary, bronchial: gastrointestinal, genito-urinary carcinomas, lymphomas, and sarcomas. Disseminated disease is associated with the highest levels; hence PAM exhibits this characteristic stage-dependent phenomenon of tumour-index substances in general. However, it remains to be established whether it is a product of the tumour cells themselves, the rnacrophages in the tumour, or of other host cells outside the tumour.
Plasma PAM levels appear to be of value in monitoring the progress of disease and its response to therapy. Falling levels occur after apparently successful surgery (Fig. 10) . Rising titres can develop with a useful and significant lead time before overt metastases are noted ( Fig. 11) . Further sequential studies of a variety of tumours apart from multiple myeloma and the lymphoid malignancies, many other types of neoplasms may be associated with monoclonal immunoglobulins in the serum. In their series 7 % of 807 patients showed monoclonal immunoglobulins. It appeared with an unexpectedly high frequency in lung and bladder cancer. This situation is not unlike that for the Regan isoenzyme, in which a large-scale initial survey of sera is necessary to find out if the patient produces this type of response. Provided it is consistent it can be a powerful discriminant in an individual monitoring array, but it has no value if it is negative. It is in the myelomas and lymphoid malignancies, however, that monitoring of specific levels can be most valuable.
In conclusion, while few, if any, of these changes may be ascribed solely to neoplasia, their measurement by modem methodology is relatively easy in large numbers. Sequential assays may help, in association with tumour products and by providing data for multiparametric discriminant analyses, in yielding an earlier warning method of recurrent and metastatic disease.
Urinary hydroxyproline
Almost all of the body's hydroxyproline (OHP) is a constituent of collagen, two-thirds of which is found in the skeleton (Lindstedt and Prockop, 1961; Neuman and Logan, 1950) . Studies of its metabolism have shown that the urinary excretion of OHP is related to bone matrix turnover (Prockop and Kivirikko, 1967) . It is, thus, not surprising to find that OHP excretion is elevated in bone diseases where there is increased turnover such as some endocrine diseases and rheumatoid disease and in osseous metastatic cancer (Ziff et al., 1956; Benoit et al., 1963; Kivirrikko et al., 1964; Guzzo et a/., 1969) . Guzzo et al., (1969) observed that the output of urinary hydroxyproline was increased not only with osseous but also with soft tissue metastases. However, by expressing the hydroxyproline output as a OHP/creatinine ratio,elevated values for this ratio were restricted to patients with bone metastases. Similar findings were noted by Cushieri and Felgate (1972) . Urinary hydroxyproline is raised in most subjects with overt metastases, irrespective of the primary tumour type (Guzzo et a/., 1969; Cushieri and Felgate, 1972; Radom et al., 1972; Powles et al., 1975) . Of greater interest and potential clinical importance, however, has been the observation that a raised OHP/creatinine ratio may exist prior to the overt development of bone secondaries as determined clinically, radiologically, or by scintiscanning. Sequential follow-up studies have shown that such raised levels may be noted for up to nine Biochemical monitoring of cancer 301 months before those other techniques detect their presence (Guzzo et al., 1969; Cushieri and Felgate; . Correspondingly, when the values stay within normal limits it is rare, but not unknown, for osseous metastases to develop. It should be remembered, however, that elevated OHP/creatinine levels can occur with finger clubblng--e.g., in lung cancer in the absence of other bone diseases-and is therefore not necessarily pathognomic of bone secondary disease.
Several authors have examined the value of OHP/ creatinine ratio output in relation to the biochemical parameters such as the serum level of alkaline phosphatase and urinary calcium output and found it to be significantly better and probably the most sensitive index of bone metastases at present available (Radom et al., 1972) . It has, however, the drawback of requiring more than a blood test and is therefore less suited to use in the elderly. Plasma assays of hydroxyproline are thus urgently needed.
The OHP/creatinine ratio is also of value in assessing the efficacy of chemotherapeutic and endocrine measures to control established osseous metastases (Powles et a/., 1975) . A decline in the ratio, indicating therapeutic efficacy, can be seen some 2-8 weeks before other indices of tumour regression are noted. On the other hand a rising ratio indicating disease deterioration may be noted up to 26 weeks before there was other evidence of an inadequate therapeutic response. Hence, by using this index it may be possible in future to adjust the therapy, its type, and/or amount with improved results. This may be all the more important if the sequential assay of the OHP/creatinine ratio is carried out from the time of initial primary diagnosis, as urinary titres in the absence of other overt disease may enable treatment to be begun earlier and changed earlier if therapeutic inadequacy is apparent on this biochemical basis.
MULTlPARAMETRIC AND LoNGITUDINAL STUDIES
In the discussion so far, we have dealt largely with the monitoring role of single tumour products or associated changes, although reference has been made to the potential value of more than one parameter and their simultaneous assay. Certainly the multiple production of ectopic factors is well recognized (Rees and Ratcliffe, 1974) and the possibility of their being produced by different cells of the tumour gives added importance to their total measurement (Rosen et al., 1975) .
Multiparametric assays have already proved of significant value in several fields. In the diagnostic area all cases of hepatoma may be detected by combined AFP and prolyl hydroxylase assays (McGee et a1., 1975) , and the detection of bronchial carcinoma is raised by the measurement of three discordant markers-namely, HCG, and sub-units, HPL, and placental alkaline phosphatase (Charles et a1., 1973; Sussman et al., 1974; Rosen et al., 1975) .
Our own studies Steele et al., 1974; Cooper et al., 1975a) have shown the value in the earlier detection of hepatic metastases from colorectal carcinoma as opposed to those at other sites by the simultaneous assay of CEA and the enzyme GGT. Although dealing with a rare tumour, namely malignant teratoma, the report of dissociated chemotherapeutic effects as judged by different changes in the plasma levels of HCG and AFP draws attention to the need of several markers, as they may be being formed by different cells, which in turn may have varying sensitivities to various therapeutic regimens (Braunstein et al., 1973) . Finally, Tormey et al. (1975) have measured a series of parameters and found that three, the f3 subunit of HCG, CEA, and the nucleoside N",N"-dimethylguanosine were together raised in 97 % of patients with metastatic breast cancer and 67 % of these with positive axillary node involvement at the time of mastectomy and who were now in the postoperative phase and apparently free of disease. These findings could therefore have important prognostic implications and be of value in selecting subjects who might benefit from forms of adjuvant therapy.
Nonetheless, the use of multiple parameters will not by themselves necessarily improve diagnosis or monitoring of disease. For example, the addition of CEX to CEA studies has not resulted in any further benefit nor has the combined measurement of AFP and CEA in lung, breast, or colorectal cancer (vide supra). Hence it is important to select with care the tumour product(s) to be measured and if possible find discordant ones. If these can be coupled to non-specific serum changes directed towards finding metastases at particular sites, then with rigorous examination of their different roles the combined use of such a battery of tests may provide new criteria for tumour evaluation and allow a more rational approach and the earlier institution of chemo-and/or immunotherapeutic programmes, together with monitoring their efficacy.
The advent of very high capacity machines for biochemical analyses and the use of multiparametric arrays as suggested in this chapter imposes special requirements for data handling. The use of repeated samples has many advantages, as they can enable the patient's own mean value to be established. A change in that mean with time may be as significant as the crossing of an arbitrary boundary defined as containing 95% of all normal values. Because of the lack ofspecificity of the various tets considered in this article, it is more likely that patterns of change in the various components in an array will be more indicative of raising the likelihood of recurrence or metastatic cancer than the result of change of any single variable. Obviously the interpretation of these results requires knowledge of the patient's health, nature of the original tumour and its probability of recurrence. The frequency of testing should probably not be longer than six months and ideally every three months. The latter introduces additional problems of whether the patient is to be seen by a medical practitioner at each visit. It is probable that a questionnaire completed by the patient or with the aid of paramedical personnel would be adequate, with the patient being examined according to the clinician's normal routine, recalled for further examination, and undergo additional investigations if there are changes in the biochemical profile. Such test systems must complement the skills of the clinician and not try to act as a substitute.
The complexities of the statistics of multiparametric analyses in time-based longitudinal studies are still in their early days of development. Readers wanting further detailed information of this subject may find the articles by Weldon and Mackay (1972) on screening tests and definition of normality and those by Rosenblatt (1963) and Cox and Lewis (1966) on time-based series analyses a useful starting point for what may prove to be a journey into largely uncharted territory.
It is to be hoped the statisticians will now come to our aid to devise systems to handle these data, creating a synthesis of the numerical data from the laboratory, clinical assessment, and antecedent factors to render it in probabilistic terms, so that the result will indicate to the clinician whether he has reached a decision point in the management of his patient. The acid test will be if all this can improve the treatment of systemic cancer which is beyond the surgeon's knife or radiotherapist's rays.
